Hot Pharma Stocks / Ideen / Blockbuster

  • b00n hat am 20.03.2012 - 17:54 folgendes geschrieben:


    wb Vagnum, hast ja gerade volltreffer gelandet. smiley

    yeah. guter Anfang, thanks. ROSG hat bei 1.00$ noch ein offenes Gap zu schliessen, vielleicht sieht man die katie noch höher irgendwann dieses Jahr. Offering war auch um 1.00$ herum.

    Bist du noch drin bei TLON 0.70$? morgen ist ja das Panel. Hab ne 2te Zockerposi eingenomen. Was denkst du? bin mir bei TLON überhaupt nicht sicher....


  • vagnum hat am 20.03.2012 - 20:40 folgendes geschrieben:

    TLON out. Adam hat mir zu fest geschossen, gepaart mit nem fund sell.

    fact ist survival 2mt.. Leuke. endstadium. Adam hat angekreidet dass menschen während der trials gestorben sind. Ich glaub sowas passiert im oder ohne Mariqbo. nur hat das keinen interessiert während des panic selling

    Ich tippe trotzdem auf ein knappes ja beim voting.

  • b00n hat am 20.03.2012 - 21:13 folgendes geschrieben:

    graz! Vagnum! 2ter treffer

  • b00n hat am 21.03.2012 - 17:15 folgendes geschrieben:


    graz! Vagnum! 2ter treffer

    jaa so machts spass. :) hab die Profitchen bei TLON mitgenommen.

    PANEL Vote war : 7 ja 4 nein 2 enthaltung. May 13 2012 Zulassungstermin.

  • CVM mal vorübergehend 20k stk verkauft, über 4k Gewinn, 5k stk behalt ich mal.

    Ganze Kohle bei GLUU und DLGC geparkt und auch bereits mit beiden Posis in der Gewinnzone.

    Plane zur gegebenen Zeit wieder CVM aufzustocken, zuerst mal sehn wies sich entwickelt.

  • AFFY 16.00$

    Affymax Wins Approval of Drug for Anemic Kidney Patients

    By Anna Edney on March 27, 2012

    Affymax Inc. (AFFY) won U.S. approval for Omontys, an anemia-treatment competitor to Amgen Inc. (AMGN)medicines that have been the only option for patients with loss of kidney function for more than 20 years.

    The Food and Drug Administration cleared Omontys, also known as peginesatide, for patients with chronic kidney disease on dialysis, according to a statement from the agency today. The treatment will be Palo Alto, California-based Affymax’s first marketed product.

    Approval of the drug -- intended to be used once a month instead of as often as three times a week for Amgen’s Epogen -- may potentially save money for Medicare, the federal health program for the elderly and disabled. Peginesatide may generate as much as $700 million in peak sales by 2017, Ian Somaiya, an analyst at Piper Jaffray & Co. in New York, said in a telephone interview.

    “We’re dealing with a monopoly right now and that’s not ideal because it’s occurred for two decades,” Somaiya said of Epogen. “Small and medium dialysis centers are price sensitive. Peginesatide would be the choice for these dialysis providers.”

    Dialysis removes toxins from the blood when kidneys can’t.

    Amgen’s Epogen, approved in 1989, generated $2 billion in sales last year, down 19 percent from 2010, according to data compiled by Bloomberg. Peginesatide may compete to a lesser extent with Thousand Oaks, California-based Amgen’s Aranesp, which is primarily used on non-dialysis kidney patients. Aranesp had $2.3 billion in sales last year.

    JNJ’s Procrit Agreement

    Johnson & Johnson’s Procrit is the same drug as Epogen though is used only in patients who aren’t undergoing dialysis under an agreement the New Brunswick, New Jersey-based drugmaker has with Amgen, Somaiya said.

    Affymax has a profit-sharing agreement for peginesatide with Osaka, Japan-based Takeda Pharmaceutical Co. (4502)

    Medicare spent $6.8 billion on dialysis and drugs for kidney failure patients in 2007, according to a March 2010 report from the U.S. Government Accountability Office, the investigative arm of Congress. Medicare, which covers almost everyone with kidney failure regardless of age, began reimbursing for such services in one bundled payment last year to save money.

    DaVita Deal

    Like peginesatide, Epogen is for anemia in chronic kidney disease patients on dialysis while Aranesp can also treat patients not on dialysis. The medicines are part of a class of drugs known as erythropoiesis-stimulating agents that boost production of red blood cells. The FDA recommended in June that doctors use the lowest possible doses of the agents because of potential heart risks. The agency in 2006 first warned that high doses of the anemia drugs may cause heart attacks and strokes.

    Amgen, the world’s largest biotechnology company, has deals with the two largest dialysis providers DaVita Inc. (DVA) of Denver and Fresenius Medical Care AG (FME) in Bad Homburg, Germany. The deal with DaVita is exclusive and for seven years, while Fresenius’s agreement isn’t exclusive and is for an undisclosed amount of years.

    To contact the reporter on this story: Anna Edney in Washington at

    To contact the editor responsible for this story: Reg Gale at

  • Neostem NBS heiss, Kursvervielfacher ist möglich ... braucht einfach zeit, kaufen und liegenlassen…-1?puc=yahoo&cm_ven=YAHOO

    PRESS RELEASE: NeoStem to Present at Three Investor Conferences in September
    04.09.12 12:35:24- DJPN

    Neostem (US6406503051)


  • CYCC 8.00$

    Cyclacel Pharmaceuticals Inc. : Cyclacel to Report New Sapacitabine Clinical Data at the American Society of Hematology Annual Meeting

    12/04/2012| 09:47am US/Eastern

    BERKELEY HEIGHTS, N.J., Dec. 4, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders announced today that updated Phase 3 clinical trial results for the treatment of elderly patients with newly diagnosed acute myeloid leukemia (AML) treated with sapacitabine and decitabine administered in alternating cycles will be presented at a poster presentation during the 54th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, on Sunday, December 9, 2012.

    The poster's abstract details are as follows:

    Title:Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles
    Date/Time:Sunday, December 9, 2012, 6:00 PM - 8:00 PM Eastern Time
    Hall B1-B2, Level 1, Building B (Georgia World Congress Center)
    Session:Acute Myeloid Leukemia - Therapy, excluding Transplantation: Poster II
    Poster board:The abstract is available online at:

    About Cyclacel Pharmaceuticals, Inc.

    Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. The Company's most advanced oral product candidate, sapacitabine, is the subject of SEAMLESS, a Phase 3 trial being conducted under an SPA with the FDA as front-line treatment of acute myeloid leukemia (AML) in the elderly and Phase 2 studies for AML, myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL) and solid tumors including breast, lung, ovarian and pancreatic cancer. Cyclacel's pipeline includes seliciclib, a CDK inhibitor, in Phase 2 for lung and nasopharyngeal cancer and in Phase 1 in combination with sapacitabine; and CYC065, a second generation CDK inhibitor, in IND-directed development. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. Please visit for additional information.

    [Blocked Image:]

  • SNTS wunderschöner jahreschart..wohin geht die reise? evtl. bis 18 bucks

    Da gibts ja noch Pharming Group N.V.(AMS:PHARM) ( 0.023)

    Der kleine Partner aus Holland welcher mit SNTS bald Ruconest bei der FDA vorlegen wird...

    Bei einem erfolg könnte SNTS den Holländer ja übernehmen...

  • eine meiner alten lieben lol :)

    Rexahn Pharmaceuticals, Inc.

    (NYSEAMEX:RNN) 0.32

    Burrill initiates coverage on Rexahn Pharmaceuticals Inc. (NYSE[Blocked Image:]: RNN) with a Market Outperform rating and $1 price target.

    "We believe that Rexahn's promising pipeline in oncology and CNS disorders is undervalued, and a successful result in any of the ongoing trials may offer significant upside for investors with high risk tolerance."

    They called Rexahn's leading oncology drug, Archexin, "promising" and see a robust pipeline. Rexahn has licensed RX-3117, one of the clinical-stage compounds to Teva and has already received $8MM in upfront and milestone fees.

    The firm's analysis suggests that Rexahn is undervalued based on the maturity of its pipeline, and based on comparable company analysis they derive an enterprise value of $131MM for Rexahn. They estimate a cash balance of $10MM by YE13 (assuming milestone payments from Teva, netting $4MM), resulting in their 12-month price target of $1.